Study at a glance
What question did the studies ask?
Does vitamin D improve the formation of immune memory, later responses or lasting protection? Human studies examined vaccines, skin responses and immune cells. One experiment studied mice lacking the vitamin D receptor, a protein through which vitamin D signals.
What did they find?
Several vaccine trials did not establish a benefit. A small tetanus study found a larger rise in one antibody measure, but not measured memory B cells. An uncontrolled study found improved skin responses in older adults. The mouse study found a narrower range of memory responses without the receptor, while several other responses were preserved.
What does this mean?
Antibodies, cell measurements and local skin responses answer different questions. A change in one does not establish stronger protection throughout the body or over many years.
What are the limits?
The studies differed in age, vitamin D status and treatment timing. Some were small or observational. The mouse experiment is not a test of ordinary supplementation in people. The evidence does not establish lasting immune-memory benefits from extra vitamin D.
Read the full article below ↓Vitamin D research does not yet establish that supplementation creates stronger, longer-lasting immune memory in people. Studies address different parts of the question: responses during a vaccine course, reactions to a later booster, immune-cell patterns with age, and protection against subsequent infection. These findings need to be compared without treating them as interchangeable measurements. This review examines memory formation first, then recall and persistence across age. For the shorter account, read Vitamin D, Immune Memory Formation and Recall Across Age: Study Summary.
Formation, recall and persistence are different questions
Immune memory concerns responses after an earlier encounter with a particular antigen, a substance recognised by the immune system. A first vaccine response can provide evidence about initial activation, but an antibody measurement soon afterwards does not by itself establish how long protection will last. A booster tests a different situation because participants already have an immune history. Repeated measurements over a substantial interval are needed to investigate persistence directly.
The distinction is central to Vitamin D and Adaptive Immunity. Antibodies, memory B cells and memory T cells describe related parts of adaptive immunity, rather than alternative names for the same outcome. A study may find a change in one while finding no change in another. Clinical infection adds a further level: exposure, pathogen characteristics and other defences also influence whether an infection occurs. It cannot be read as a direct count of memory cells.
Vitamin D exposures also differ. Supplementing vitamin D3 changes the supply of a precursor; measuring circulating 25-hydroxyvitamin D describes a blood marker; deleting the vitamin D receptor in an animal changes the ability to respond to that signalling pathway. These are not equivalent experiments. The surrounding regulation is introduced in Vitamin D and Immune Modulation, but participation in regulation does not establish a benefit from additional supplementation.
Formation following vaccination: association and intervention
Kashi and colleagues reported two separate investigations of hepatitis B vaccination in healthy young military adults. Their prospective cohort included 447 analysed participants. Some vitamin D and seasonal comparisons were associated with antibody response, although the conventional 50 nmol/L division did not provide a statistically significant contrast. Season can accompany other differences in exposure and behaviour. An association with a blood concentration therefore cannot identify the effect of assigning a supplement.
The same publication also reported a separate randomised trial. It randomised 231 participants, with 119 included in the analysis, and tested oral vitamin D3 and simulated sunlight against their respective controls. Supplementation began three days after the first vaccine dose. The oral regimen used 1,000 international units (IU) daily during restoration and 400 IU daily during maintenance over a 12-week intervention. At baseline, 75% had 25-hydroxyvitamin D below 50 nmol/L. Responders were defined by antibodies to hepatitis B surface antigen of at least 10 mIU/mL. Oral-treatment and oral-placebo responder proportions were 56% and 52%; the simulated-sunlight and its placebo proportions were 60% and 57%. None established a treatment advantage. These were separate study populations, not a favourable observational result replicated by a favourable trial.
The timing is important. The trial does not test whether correcting low status well before the first vaccine exposure changes initial priming. Equally, the absence of that test is not evidence that earlier treatment would work. Antibodies were assessed after the second vaccine dose and before the final dose of the course. Attrition, a smaller analysed sample than planned, and the incomplete vaccine course at assessment restrict conclusions about eventual protection. Long-term memory was not demonstrated by either study.
Gonçalves-Mendes and colleagues studied 38 adults older than 65 with 25-hydroxyvitamin D below 30 ng/mL (75 nmol/L), the study’s low-status entry criterion. Six 100,000 IU vitamin D3 doses, one every 15 days, or placebo were given over three months before influenza vaccination, and antibody outcomes were assessed 28 days afterwards. This supplies a useful contrast to the later intervention start in Kashi’s trial. It did not demonstrate an overall improvement in vaccine antibody responses; some strain-specific comparisons favoured placebo. Cathelicidin, an antimicrobial peptide, did not show a treatment benefit either.
The small trial was under its intended recruitment target and examined several outcomes. It cannot establish exact equivalence or exclude every modest effect. Nevertheless, its pre-vaccination treatment and deficient older population prevent a simple explanation in which every negative trial involved only vitamin-D-replete young adults treated too late. The findings should remain attached to this vaccine, population and short follow-up. Wider B-cell evidence is examined in Vitamin D, B-Cell Function and the Limits of Immune Memory Evidence: Full Evidence Review.
The CORONAVIT vaccine substudy examined a larger and different setting. Its vaccinated cohort comprised 2,808 participants, with antibody testing in 1,853 and cellular assays in a much smaller subgroup. An open-label test-and-treat strategy offered 800 or 3,200 IU vitamin D3 daily when 25-hydroxyvitamin D was below 75 nmol/L. Adjusted breakthrough-infection hazard ratios were 1.28 (95% confidence interval 0.89 to 1.84) and 1.17 (0.81 to 1.70), respectively. Both intervals include no difference; neither establishes protection. The analyses did not establish better vaccine immunogenicity or fewer breakthrough infections under that strategy. Cellular findings also did not supply a convincing advantage after accounting for multiple comparisons.
CORONAVIT’s vaccine analysis was not simply the parent trial’s complete intention-to-treat population. Selection of adherent supplemented participants and unsupplemented controls, unknown baseline vitamin D status in controls, and limited follow-up constrain interpretation. Its contribution is a clinically relevant test that did not demonstrate the proposed improvement. It does not prove that vitamin D has no immune role, nor does it establish memory maintenance over many years.
The reported doses identify the experiments being compared; they are not recommendations. A daily regimen, an intermittent large dose and receptor deletion answer different questions. This review does not establish a safe or effective personal dose.
What the animal receptor experiment adds
Yuzefpolskiy and colleagues compared mice lacking the vitamin D receptor with wild-type mice. CD8 T cells are immune cells involved in responses against infected cells. Receptor-deficient mice showed a narrower range of antigen-specific responses, with reduced response diversity still evident at the 150-day memory assessment. It therefore supplies mechanistic evidence relevant to memory formation after infection, rather than merely another blood-concentration association. However, several broad memory-subset and cytokine co-production comparisons were preserved rather than uniformly impaired.
Lifelong absence of the receptor is a major biological alteration. It is not equivalent to a moderately low vitamin D result in an adult, and it does not estimate the effect of a supplement in a vaccinated person. Groups of three to five mice and one-tailed statistical comparisons further limit precision. The experiment supports a bounded biological relationship; it cannot establish a human treatment threshold, an optimal intake or a universal improvement in memory function.
Early immune responses also involve the processes introduced in Vitamin D and Innate Immunity. Their interaction with adaptive responses is a relevant relationship, but neither an antimicrobial-peptide result nor an early inflammatory signal is itself proof of antigen-specific memory. The evidence here does not justify extending the mouse findings into a claim that vitamin D improves every kind of immune adaptation.
Recall responses: a booster and a local skin challenge
Heine and colleagues examined tetanus booster responses in 32 adults, with 20 receiving 2,000 IU vitamin D3 daily for ten weeks and 12 receiving placebo. Calcium intake was supported in both groups. The booster followed nine weeks of supplementation, and antibody responses were examined about a month later. A modest IgG antibody difference was reported with a nominal P value of 0.04. The study did not demonstrate corresponding improvements in IgA, measured memory B-cell frequency, plasmablasts or the assessed cytokine responses.
This is a useful example of why a favourable antibody result should not be renamed a general memory benefit. The groups were small and unequal, several outcomes were tested, and some cellular analyses involved fewer participants. An estimate or discussion of how long antibodies might remain above a threshold is not the same as observing participants over that interval. The trial supplies a short-term booster finding, not direct evidence of five: or ten-year protection.
Chambers and colleagues investigated a different recall setting in 18 older adults with 25-hydroxyvitamin D below 75 nmol/L, before and after 14 weeks of vitamin D3 at 6,400 IU daily. The overall clinical skin response to varicella-zoster antigen improved. In the paired gene-expression analysis of 16 participants, seven were classified as improving by at least two points on the clinical response score. The work linked local inflammatory conditions with the capacity to express a recall response in the skin.
There was no randomised placebo group. Changes with time, repeated measurement and differences between responder subgroups cannot be separated confidently from treatment effects. The whole-group antigen-related gene-expression comparison did not show significant differential findings, and circulating inflammatory markers did not clearly improve. These null measurements should be distinguished from the improved overall clinical skin score. The result is therefore a promising local functional observation, not proof that supplementation reverses immune ageing or prevents shingles. Vitamin D and Immune Ageing introduces the broader age-related question; the local response should not be expanded into a whole-body outcome.
Ageing changes the interpretation of cell profiles
Hwang and colleagues examined vitamin D concentrations and CD8 T-cell patterns in 34 healthy women older than 60. Higher concentrations were associated with fewer cells classified as naïve and more classified as effector cells. This was a cross-sectional comparison, not a supplementation trial following the development of memory. The investigators did not establish corresponding differences across several functional or senescence-related measurements.
The association cannot show that vitamin D caused immune ageing, and it cannot show that a larger experienced-cell fraction meant better protective memory. The sample was small, racial composition differed across vitamin D groups, and the association was less secure in a restricted comparison. Supplement use and other influences were not fully resolved. Cell composition is informative, but the direction of a desirable change depends on the biological question and functional evidence.
Age therefore cannot be treated as one uniform background variable. The healthy older women in Hwang’s analysis, deficient influenza-vaccine participants and older adults undergoing a skin recall test were different populations. Vitamin D in Older Adults provides the life-stage context. None of these studies followed an entire sequence from altered vitamin D signalling, through memory-cell maintenance, to reliably preserved protection over many years.
A later infection is not a direct memory assay
Di Filippo and colleagues’ retrospective breakthrough-infection study adds an observational clinical outcome. In 114 endocrine outpatients, the unadjusted comparison was more favourable among people receiving longstanding cholecalciferol. After matching, infections occurred in 7 of 39 supplemented participants and 14 of 39 comparison participants; that contrast was not statistically significant. Presenting only the unmatched result would exaggerate the certainty.
Vitamin D measurements were historical rather than a consistent measurement at vaccination. Residual differences in health, behaviour and exposure, small event counts, multiple analyses and missing information restrict causal interpretation. The paper does not directly measure memory cells. Its programme is linked to another report on Long COVID, and participant-level independence has not been established; the reports should not be counted as independent confirmations of one causal benefit.
What each type of evidence can establish
| Measurement | Useful question | Important limit |
|---|---|---|
| Antibodies during a vaccine course | Did this measured response differ at that time? | Does not establish completed-course protection or durable memory |
| Booster response | Did prior immune experience produce a different short-term response? | Does not itself measure years of persistence |
| Memory-cell or cell-subset measurements | Did a defined population or property differ? | Cell frequency is not the same as effective protection |
| Local skin recall | Did antigen-specific response in this tissue change? | Does not establish systemic immune restoration |
| Subsequent infection | Did a clinical event differ under observed exposure? | Exposure and other defences prevent a memory-specific interpretation |
The table also explains why chronic inflammation cannot be used as a substitute outcome. A lower inflammatory marker might accompany a change in immune function, but the connection must be demonstrated. The related evidence in Vitamin D, Long-Term Inflammation, Biological Ageing and Metabolic Risk: Full Evidence Review concerns inflammation and biological ageing; it does not supply the missing longitudinal proof of memory maintenance for these vaccine and recall studies.
Conclusion and remaining uncertainty
The human evidence includes several null vaccine comparisons, a small favourable booster-antibody finding, and an uncontrolled local recall observation in older adults. The mouse experiment supports receptor involvement in memory-related biology, while the cross-sectional cell study complicates any assumption that higher vitamin D automatically means a younger or more capable immune system. These findings are complementary questions, not votes for one universal effect.
Long-term preservation remains the central unresolved issue. A convincing answer would need repeated, relevant memory and functional outcomes over sufficient follow-up, alongside a design capable of separating vitamin D effects from other influences. The present evidence does not establish that supplementation improves durable immune memory following infection or vaccination. That uncertainty neither erases vitamin D biology nor supplies a reason to promise better vaccine protection from additional supplementation.
The review uses the assessed principal papers and claim-relevant main results. Some supplementary material and exact graph-derived values were unavailable or not fully verified; claims requiring them are not made. Levin and colleagues’ 2024 zoster-vaccine report (Vaccine, DOI 10.1016/j.vaccine.2024.02.055) was identified, but its complete principal paper was unavailable; it is not used to establish a treatment effect or counted as an assessed independent trial. These access limits leave the evidence incomplete rather than turning missing information into a favourable conclusion.
Sources
Related reading
Association between milk consumption in middle age and frailty in later life: The Aichi Workers' cohort study
Therefore, we carried out an investigation to explore the association between milk consumption during middle age and development of frailty examined after over 15 years of follow up in a long‐term cohort study in Japan.
Original paper ↗Read more →Impact of Vitamin D Supplementation on Influenza Vaccine Response and Immune Functions in Deficient Elderly Persons: A Randomized Placebo-Controlled Trial
This randomized placebo-controlled double-blind trial investigated whether Vit-D supplementation in deficient elderly persons could improve influenza seroprotection and immune response.
Original paper ↗Read more →Vitamin D Supplementation Does Not Influence SARS-CoV-2 Vaccine Efficacy or Immunogenicity: Sub-Studies Nested within the CORONAVIT Randomised Controlled Trial
Sub-study 1 (n = 2808) investigated the effects of vitamin D supplementation on the risk of breakthrough SARS-CoV-2 infection following two doses of SARS-CoV-2 vaccine.
Original paper ↗Read more →Vitamin D3 replacement enhances antigen-specific immunity in older adults
We investigated the use of vitamin D3 replacement to enhance cutaneous antigen-specific immunity in older adults (≥65 years).
Original paper ↗Read more →Vitamin D, Immune Memory Formation and Recall Across Age: Study Summary
A plain-English guide to vitamin D, vaccination, immune recall and ageing.
Read more →Vitamin D supplementation for prevention of acute respiratory infections in older adults: A systematic review and meta-analysis
Therefore, we systematically reviewed evidence from randomized controlled trials (RCTs) to evaluate the efficacy and safety of vitamin D supplementation in preventing ARIs in older adults.
Original paper ↗Read more →A Cross-Sectional Study of Nutrition Knowledge, Diet Quality, Lifestyle, and Health Profiles Among Older Adults Attending Universities of the Third Age in Poland
This study aimed to assess these associations among older adults attending U3A in Poland.
Original paper ↗Read more →Effects of micronutrient supplementation on immune function in older adults: a meta-analysis
This systematic review and meta-analysis of randomized controlled trials (RCTs) evaluate the impact of micronutrient supplementation on immune function in older adults.
Original paper ↗Read more →Association of Vitamin D Supplementation with VDR and CAMP Expression and Ulcer Healing in Diabetic Foot Infection Involving Biofilm-Forming Bacteria: An Exploratory Prospective Cohort Study
This study investigated the association between vitamin D supplementation, the vitamin D: VDR: CAMP: LL-37 pathway, and ulcer healing in DFIs involving biofilm-forming bacteria.
Original paper ↗Read more →Epidemiology of viral and atypical bacterial respiratory infections among children hospitalised at a Kenyan tertiary referral centre: a cross sectional multiplex PCR study
Severe acute respiratory infections (SARIs) cause high paediatric morbidity and mortality particularly in sub-Saharan Africa.
Original paper ↗Read more →Adjunct Tendon Vibration and Bone Outcomes in Older Adults with Osteoporosis: A 12-Month Prospective Cohort Study
This 12-month prospective non-randomised controlled cohort study included 100 adults aged ≥60 years with DXA-confirmed osteoporosis recruited from orthopaedic clinics in the Greater Thessaloniki area.
Original paper ↗Read more →Change of vitamin D status and all-cause mortality among Chinese older adults: a population-based cohort study
We aimed to study the relationship between vitamin D change and all-cause mortality among older Chinese adults including the oldest old.
Original paper ↗Read more →Effect of Monthly Vitamin D Supplementation on Preventing Exacerbations of Asthma or Chronic Obstructive Pulmonary Disease in Older Adults: Post Hoc Analysis of a Randomized Controlled Trial
Randomized controlled trials have suggested that vitamin D supplementation can prevent asthma and chronic obstructive pulmonary disease (COPD) exacerbations.
Original paper ↗Read more →Epicardial fat and insulin resistance in healthy older adults: a cross-sectional analysis
The study aimed at assessing the relationship between epicardial fat (EF), an indicator of cardiovascular risk, and IR in Italian free-living elderly (n = 89).
Original paper ↗Read more →Factors associated with cognitive function outcomes among older adults in Kuwait: A cross-sectional study
A normal MMSE score was reported for 51.0% (n = 129) of the sample, with 34.7% and 14.2% of participants having mild and moderate/severe cognitive impairment, respectively.
Original paper ↗Read more →Low Vitamin D Levels and Frailty Status in Older Adults: A Systematic Review and Meta-Analysis
Serum vitamin D deficiency is widespread among older adults and is a potential modifiable risk factor for frailty.
Original paper ↗Read more →Prevalence and clinical characterization of malnutrition, sarcopenia and sarcopenic obesity in older adults with cardiometabolic diseases: SENIOR cross-sectional study
This study examined their prevalence and overlap in older adults with cardiometabolic diseases and explored associations with metabolic syndrome, multidimensional health-related factors and inflammation.
Original paper ↗Read more →Smoking, alcohol consumption, drug abuse, and osteoporosis among older adults: a cross-sectional study on PERSIAN cohort study in Fasa
Our study aimed to explore the correlation between smoking, alcohol consumption, and drug abuse among older adults and the incidence of osteoporosis.
Original paper ↗Read more →Vitamin D Status and Associated Factors of Older Adults in the Cross-Sectional 2015 to 2017 Survey
In the study, a total of 6273 participants were included.
Original paper ↗Read more →Vitamin D and Immune Memory
Explains how vitamin D relates to immune memory, T and B cells, cytokine signalling, antigen presentation, immune ageing, and long-term immune readiness.
Read more →Vitamin D, B-Cell Function and the Limits of Immune Memory Evidence: Full Evidence Review
A review of B-cell experiments and vaccine trials, separating memory-cell markers and antibody changes from lasting protection against infection.
Read more →Original sources
Vitamin D and the hepatitis B vaccine response: a prospective cohort study and a randomized, placebo-controlled oral vitamin D3 and simulated sunlight supplementation trial in healthy adults
Kashi et al. (2021). Vitamin D and the hepatitis B vaccine response: a prospective cohort study and a randomized, placebo-controlled oral vitamin D3 and simulated sunlight supplementation trial in healthy adults.
Publication details
Kashi et al. (2021). Vitamin D and the hepatitis B vaccine response: a prospective cohort study and a randomized, placebo-controlled oral vitamin D3 and simulated sunlight supplementation trial in healthy adults. European Journal of Nutrition. 60(1):475. DOI: 10.1007/s00394-020-02261-w.
Impact of Vitamin D Supplementation on Influenza Vaccine Response and Immune Functions in Deficient Elderly Persons: A Randomized Placebo-Controlled Trial
This randomized placebo-controlled double-blind trial investigated whether Vit-D supplementation in deficient elderly persons could improve influenza seroprotection and immune response.
Publication details
Gonçalves-Mendes et al. (2019). Impact of Vitamin D Supplementation on Influenza Vaccine Response and Immune Functions in Deficient Elderly Persons: A Randomized Placebo-Controlled Trial. Frontiers in Immunology. 10:65. DOI: 10.3389/fimmu.2019.00065.
Vitamin D Supplementation Does Not Influence SARS-CoV-2 Vaccine Efficacy or Immunogenicity: Sub-Studies Nested within the CORONAVIT Randomised Controlled Trial
Sub-study 1 (n = 2808) investigated the effects of vitamin D supplementation on the risk of breakthrough SARS-CoV-2 infection following two doses of SARS-CoV-2 vaccine.
Publication details
Jolliffe et al. (2022). Vitamin D Supplementation Does Not Influence SARS-CoV-2 Vaccine Efficacy or Immunogenicity: Sub-Studies Nested within the CORONAVIT Randomised Controlled Trial. Nutrients. 14(18):3821. DOI: 10.3390/nu14183821.
Vitamin D Receptor Signals Regulate Effector and Memory CD8 T Cell Responses to Infections in Mice
Yuzefpolskiy et al. (2014).
Publication details
Yuzefpolskiy et al. (2014). Vitamin D Receptor Signals Regulate Effector and Memory CD8 T Cell Responses to Infections in Mice. The Journal of nutrition. 144(12):2073-2082. DOI: 10.3945/jn.114.202895.
Efficient tetanus toxoid immunization on vitamin D supplementation
Published in European journal of clinical nutrition. 65(3):329-334. DOI: 10.1038/ejcn (2010).
Publication details
Heine et al. (2011). Efficient tetanus toxoid immunization on vitamin D supplementation. European journal of clinical nutrition. 65(3):329-334. DOI: 10.1038/ejcn.2010.276.
Vitamin D3 replacement enhances antigen-specific immunity in older adults
We investigated the use of vitamin D3 replacement to enhance cutaneous antigen-specific immunity in older adults (≥65 years).
Publication details
Chambers et al. (2021). Vitamin D3 replacement enhances antigen-specific immunity in older adults. Immunotherapy Advances. 1(1):ltaa008. DOI: 10.1093/immadv/ltaa008.
Increased vitamin D is associated with decline of naïve, but accumulation of effector, CD8 T cells during early aging
Published in Advances in aging research. 2(2):72-80. DOI: 10.4236/aar (2013).
Publication details
Hwang et al. (2013). Increased vitamin D is associated with decline of naïve, but accumulation of effector, CD8 T cells during early aging. Advances in aging research. 2(2):72-80. DOI: 10.4236/aar.2013.22010.
Impact of chronic cholecalciferol supplementation and vitamin D status on risk of post-vaccination SARS-CoV-2 breakthrough infection
Di Filippo et al. (2026).
Publication details
Di Filippo et al. (2026). Impact of chronic cholecalciferol supplementation and vitamin D status on risk of post-vaccination SARS-CoV-2 breakthrough infection. Endocrine. 91(1):209. DOI: 10.1007/s12020-026-04677-6.